Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook
Novo Nordisk
warned on Tuesday that full-year sales and operating profit would grow less than previously expected, marking its second forecast cut of 2025.
The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the
obesity drug
boom against U.S. rival Eli Lilly. Novo shares have fallen sharply over the past year.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Leadership
CXO
MBA
Product Management
Artificial Intelligence
Project Management
MCA
others
Data Science
Cybersecurity
Healthcare
Operations Management
Management
PGDM
Degree
Technology
Design Thinking
Digital Marketing
Data Science
healthcare
Public Policy
Data Analytics
Others
Finance
Skills you'll gain:
Duration:
22 Weeks
Indian School of Business
SEPO - ISB Venture Capital & Private Equity India
Starts on
undefined
Get Details
Skills you'll gain:
Strategic Thinking & Planning
Competitive Advantage & Market Positioning
Strategic Leadership & Decision-Making
Change Management & Organizational Transformation
Duration:
1 Year
IIM Kozhikode
IIMK Advanced Strategic Management Programme
Starts on
Mar 30, 2024
Get Details
Skills you'll gain:
Duration:
12 Months
IIM Kozhikode
SEPO - IIMK CEO Programme India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
10 Months
IIM Indore
Executive Programme in Business Management
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK-Women Leadership Programme INDIA
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
IIM Lucknow
CERT-IIML SLP India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
12 Months
IIM Kozhikode
Senior Management Programme
Starts on
undefined
Get Details
Skills you'll gain:
Financial Accounting & Analysis
Financial Instruments & Markets
Corporate Finance & Valuation
Investment Management & Banking
Duration:
12 Months
IIM Kozhikode
IIMK Professional Certificate in Financial Analysis and Financial Management
Starts on
Mar 30, 2024
Get Details
Skills you'll gain:
Duration:
12 Months
IIM Kozhikode
Advanced Strategic Management Programme
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
18 Weeks
109820388
Strategic Marketing for Leaders: Leveraging AI for Growth
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
12 Weeks
IIM Kozhikode
CERT-IIMK EPIS Async India
Starts on
undefined
Get Details
Skills you'll gain:
Critical Thinking & Decision-Making Skills
Power of Emerging Technologies
Innovation and Drive Organizational Change
Fostering a Culture of Innovation
Duration:
9 Months
MIT xPRO
MIT Technology Leadership and Innovation
Starts on
May 14, 2024
Get Details
Skills you'll gain:
Opportunities & Outlining Plans to use AI & ML
Applying Data-Driven Business Innovation Best Practices
Changing Culture to Integrate AI-Enabled Technologies
Ethics, Privacy and Regulations in AI & ML
Duration:
20 Weeks
Indian School of Business
ISB Leadership in AI
Starts on
May 14, 2024
Get Details
"The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement.
"This is related to lower growth expectations for Wegovy in the
U.S. obesity market
, lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO markets," it said.
Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its operating profit growth forecast to 10%-16%, from a prior outlook of 16-24%.
Live Events
Economic Times WhatsApp channel
)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
15 hours ago
- Time of India
Cert-In pivots cybersecurity audits to threat readiness
Academy Empower your mind, elevate your skills ETtech The cybersecurity audit guidelines issued by the Indian Computer Emergency Response Team , or Cert-In, will revamp how such audits are approached in the country, shifting the focus from checklist-based compliance to continuous threat preparedness , experts stringent audit framework released last week is expected to compel both public and private entities to implement robust measures that not only prevent breaches but also enable real-time response amid rising cyber threats, they said.'Indian enterprises have recognised the impact due to cyber risk, and the recent spate of cyber incidents has further heightened the sensitivity. The Cert-In guidelines are timely and comprehensive,' said Atul Gupta, partner at KPMG. 'It is heartening to see the inclusion of attack vectors like VPNs, supply chains, and access controls, which have been repeatedly exploited in recent breaches.'Audits are now expected to go beyond policy declarations and cover technical configurations, evidence logs, cloud infrastructure, and even secure code has made it mandatory for cybersecurity audits to comprehensively cover an organisation's entire ICT structure, including APIs, apps, cloud, and operational technology (OT) systems, using both manual and automated testing. Auditors must follow global frameworks and report vulnerabilities to reflect severity and real-world under the electronics and IT ministry, Cert-In is the national nodal agency for noted that one of the most significant changes is the expectation for top management to take ownership of cybersecurity audit programs.'There is now a clear top-down mandate,' said Munjal Kamdar, partner at Deloitte. 'Boards must define scope, approve remediation actions, and ensure comprehensive coverage, from secure software setups to risk exception handling.'Auditors are also required to retain logs, review code, and verify secure configurations – practices that were earlier optional or inconsistently implemented.'The real opportunity is in becoming breach-ready, building programs that can detect, respond, and recover in real time,' said Sundareshwar Krishnamurthy, partner and leader, cybersecurity, at PwC guidelines also call on Cert-In-empanelled audit firms to reskill teams to keep track of audit hyperconnected applications, multi-cloud adoption, and AI-enabled platforms growing rapidly, security audits must now be conducted by teams that 'understand threat exposure and can apply professional judgment,' noted Gupta of Kamdar said, 'Audits are no longer one-size-fits-all. Technical scope, documentation, and manual testing capabilities will all have to scale up.'The Cert-In guidelines even illustrate how firms must handle audit-related data securely, restrict the use of freelancers, prohibit audit subletting, and enforce report said sectors such as banking, telecom, healthcare, and energy, which are already under regulatory pressure, will feel the impact most immediately. However, smaller firms will also have to adapt quickly.'We are seeing a mindset shift,' Krishnamurthy of PwC India said. 'Security is no longer about passing an audit, it's about protecting business continuity, reputations, and national infrastructure.'As India ramps up its cybersecurity defences amid rising attack frequency and regulatory scrutiny, these new Cert-In guidelines may well serve as a foundational believe these could also prompt the development of a more mature, standardised, and transparent cybersecurity audit system – a need long felt by both enterprises and regulators.
Economic Times
a day ago
- Economic Times
Biocon sees GLP-1 weight-loss therapy as a future growth driver
Synopsis Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 India launch. CEO Shreehas Tambe said both portfolios are complementary. Biocon aims to leverage its insulin experience for GLP-1 success, following US FDA approval for insulin aspart and India approval for liraglutide. External risks remain a key concern. ET Bureau Biocon will continue to deepen its push in the insulin business, even as the biopharmaceutical company will have GLP-1 weight-loss therapy as one of the key focus areas in its future growth strategy, Shreehas Tambe, chief executive of Biocon Biologics, told ET on decades of experience in insulin, the Bengaluru-based company aims to gain an edge over rivals in the race for copycats of GLP-1 drugs, which are gaining popularity as an effective treatment for glucose control as well as weight management. Biocon has completed bioequivalence studies in India for semaglutide, a GLP-1 drug, and is progressing to Phase-III trials, which it expects to conclude by the end of calendar year 2026.'Subsequent regulatory approval is anticipated in CY 2027, after which we will launch the product in India through a partner,' said Tambe, who is also the managing director of the biosimilar and biologics subsidiary of Nordisk's blockbuster weight-loss drug semaglutide (branded Wegovy) will go off patent in India in March. On being asked about the disruption in the diabetes drug segment due to the inroads by GLP-1 products, Tambe said: 'The disruption (due to GLP-1) is complementary to insulin. We are bullish on both insulin and GLP-1.''The originators who brought GLP1s are the insulin companies, and they were able to do that because it is synergistic. Synergy not just in terms of the therapy area but also in terms of operations, touchpoints for prescribers, healthcare givers and customers,' said Tambe, who is also the company's managing has both biosimilar insulins and GLP-1 peptides that mimic a naturally occurring gut hormone that controls sugar levels and appetite. 'That is what differentiates us from the rest,' he said.'Having been close to the market will give an advantage because it requires a lot of expertise as the drug is in the form of an injectable, given in a device, is a chronic treatment and hence requires a long-term relationship with patients who need to be trained on those devices,' said Tambe. 'All of these we have been able to do with our insulins in the past several years in 80-plus countries that is why we feel confident and we are developing both portfolios that are complementary to each other.'The company got US Food and Drug Administration approval for insulin aspart, its second interchangeable biosimilar insulin, deepening its presence in the US insulin market.'The US FDA approval of Kirsty (biosimilar aspart) builds on the strong foundation established with Semglee (biosimilar insulin glargine), enabling us to offer patients the full range of affordable short- and long-acting insulin therapies,' he said. 'Insulin aspart we will enter by the end of this fiscal,' he company got approval for diabetes drug liraglutide in India in June. The drug, used in treating type-2 diabetes, has already launched in the UK and the EU.'We are working towards expeditiously launching the drug product through our commercialisation partners in India,' said Tambe.'The biggest concern for the year ahead is external risks to the business, such as potential tariff and geopolitical headwinds. Some of these things are not in our control but that is the biggest concern for the whole industry too,' he said.
Economic Times
a day ago
- Economic Times
European shares on track for biggest weekly gain in 12; Novo Nordisk rises
European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed U.S. President Donald Trump's nomination for Federal Reserve's open spot on its governing board. ADVERTISEMENT Danish drugmaker Novo Nordisk added 3.2% and ranked among the top performers on the Stoxx 600 after rival Eli Lilly's weight-loss pill's late-stage study showed that it lagged Novo's injectable obesity treatment Wegovy. The pan-European STOXX 600 index rose 0.2%, as of 0715 GMT. Most regional bourses were also trading in the green with Spain's benchmark index IBEX up 0.4%. UK's blue-chip FTSE 100 added 0.2%, a day after the Bank of England cut interest rates by a quarter percentage point in a narrow 5-4 vote with inflation concerns weighing on the decision. Munich Re shares fell 7% and were among the top decliners on the index after the German reinsurer trimmed its fiscal-year outlook for insurance revenue due to business and foreign exchange rates. RTL Group shares added 3.1% after the European broadcaster reported its half-year results and confirmed its full-year revenue outlook. ADVERTISEMENT The world's largest online betting company Flutter raised its full-year profit growth forecast but shares fell 1.4%. Italian finance group Unipol shares fell 2.7% despite reporting a rise in first-half profit. ADVERTISEMENT Trump said he will nominate Council of Economic Advisers Chairman Stephen Miran to serve out the final few months of a newly vacant seat at the Fed while the administration looks for a permanent addition. (You can now subscribe to our ETMarkets WhatsApp channel)
